Anti-CD38 antibodies for treatment of acute myeloid leukemia

Patent metadata

Field	Value
Publication number	US-12286474-B2
Application number	US-202017005039-A
Country	US
Kind code	B2
Filing date	Aug 27, 2020
Priority date	Dec 4, 2014
Publication date	Apr 29, 2025
Grant date	Apr 29, 2025

Abstract

The present invention relates to methods of treatment of acute myeloid leukemia with anti-CD38 antibodies.

First claim

We claim:

1. A method of treating relapsed or refractory acute myeloid leukemia (AML) in a subject in need thereof, comprising administering to the subject an anti-CD38 antibody:
b) for a time sufficient to treat the relapsed or refractory AML, wherein the anti-CD38 antibody consists of daratumumab, and wherein the AML is AML with at least one mutation in a gene selected from the group consisting of fms-related tyrosine kinase 3 (FLT3), nucleophosmin (NPM1), isocitrate dehydrogenase 2 (IDH2), DNA (cytosine-5) methyltransferase 3 (DNMT3A) and CCAAT/enhancer binding protein alpha (CEBPA).

2. The method of claim 1 , wherein the anti-CD38 antibody induces killing of AML cells that express CD38 by apoptosis.

3. The method of claim 1 , wherein the anti-CD38 antibody is administered as a remission induction, post-remission or maintenance therapy.

4. The method of claim 1 , wherein the AML is AML with a mutation in FLT3, and wherein the mutation in FLT3 is FLT3-ITD.

5. The method of claim 1 , wherein the AML is AML with a mutation in IDH2, and wherein the mutation in IDH2 is R140Q.

6. The method of claim 1 , wherein the AML is AML with a mutation in DNMT3A, and wherein the mutation in DNMT3A is R882H.

7. The method of claim 1 , wherein the AML is AML with multilineage dysplasia, therapy-related AML, undifferentiated AML, AML with minimal maturation, AML with maturation, acute myelomonocytic leukemia, acute monocytic leukemia, acute erythroid leukemia, acute megakaryoblastic leukemia, acute basophilic leukemia, acute panmyelosis with fibrosis or myeloid sarcoma.

8. The method of claim 1 , wherein the subject has been treated with idarubicin.

9. The method of claim 1 , wherein the subject has been treated with cytarabine.

10. The method of claim 1 , wherein the subject has been treated with hydroxyurea.

11. The method of claim 1 , wherein the subject is further treated or has been treated with radiotherapy.

12. The method of claim 1 , wherein the subject has been treated with idarubicin, cytarabine, and hydroxyurea.

Assignees

• Janssen Biotech Inc

Inventors

• Doshi Parul
• Danet-Desnoyers Gwenn
• Dos Santos Cedric
• Sasser Amy
• Shan Xiaochuan

Classifications

• C07K2317/734

  Complement-dependent cytotoxicity [CDC] · CPC title

• C07K2317/732

  Antibody-dependent cellular cytotoxicity [ADCC] · CPC title

• C07K2317/73

  Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation · CPC title

• C07K2317/565

  Complementarity determining region [CDR] · CPC title

• C07K2317/56

  variable (Fv) region, i.e. VH and/or VL · CPC title